Last updated: November 2, 2026
Rebyota is the first FDA-approved fecal microbiota product and the first commercial entrant in microbiome-based therapy. Ferring Pharmaceuticals markets Rebyota in the United States for preventing recurrent Clostridioides difficile infection in adults after antibacterial treatment. Its commercial trajectory depends on physician adoption, payer coverage, administration logistics and competition from Vowst, an oral microbiota product. Ferring has not publicly disclosed standalone Rebyota revenue, unit sales or profitability, limiting precise financial modeling.
What is Rebyota and what is its FDA status?
Rebyota is fecal microbiota, live-jslm, formerly identified as RBX2660. It is administered rectally as a single 150 mL dose after completion of antibacterial treatment for recurrent C. difficile infection.
The FDA approved Rebyota on November 30, 2022, under Biologics License Application No. 213846. The product is manufactured and commercialized by Ferring Pharmaceuticals through its Rebiotix business. The approved indication is prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent infection. Rebyota is not approved to treat active C. difficile infection.[1]
| Category |
Rebyota status |
| Active product |
Fecal microbiota, live-jslm |
| Former development code |
RBX2660 |
| FDA approval |
November 30, 2022 |
| FDA application |
BLA 213846 |
| Dosage form |
Rectal suspension |
| Administration |
One 150 mL dose |
| Target population |
Adults with recurrent C. difficile infection |
| Manufacturer |
Rebiotix, a Ferring Pharmaceuticals company |
| Commercial launch |
United States, 2023 |
| Primary competitor |
Vowst, fecal microbiota spores, live-brpk |
| Regulatory category |
Biological product |
Rebyota received a standard FDA approval rather than an accelerated approval. The FDA based approval on clinical evidence showing reduced recurrence compared with placebo in adults at elevated risk of recurrent infection.[1]
How large is the Rebyota market?
The addressable market is narrower than the overall C. difficile treatment market. Rebyota is used after recurrent infection and antibacterial therapy, not as a first-line treatment for initial infection.
The commercial opportunity is shaped by four factors:
- Recurrent C. difficile infection creates a clinically defined population with high hospitalization and retreatment costs.
- Existing standard-of-care antibiotics, including vancomycin and fidaxomicin, do not directly replace microbiota restoration.
- Rebyota requires healthcare-site administration, which adds operational friction.
- Vowst offers oral administration and competes directly for the same recurrence-prevention population.
The U.S. market has favorable clinical economics because recurrent C. difficile can lead to repeated antibiotic courses, emergency care and hospitalization. A microbiota product can be economically attractive to payers if it reduces recurrence, even at a substantial acquisition price. Actual uptake depends on whether insurers reimburse the product and administration fee without prior authorization barriers.
What is Rebyota’s commercial positioning?
Rebyota has three principal positioning advantages:
- It was the first FDA-approved microbiota product.
- It has an established regulatory and clinical record in recurrent C. difficile infection.
- It is backed by Ferring, a global specialty pharmaceutical company with commercial infrastructure in gastroenterology and hospital medicine.
Its principal disadvantages are rectal delivery, reliance on healthcare professionals for administration and the absence of the convenience associated with oral products.
Rebyota is likely to be most competitive in hospitals, outpatient infusion or procedure centers and systems that already manage recurrent C. difficile through infectious-disease and gastroenterology programs.
What is Rebyota’s financial trajectory?
Ferring does not report Rebyota as a separately listed public-company product. Ferring Pharmaceuticals is privately held and does not provide the level of product-level revenue disclosure available from public companies such as Pfizer, Merck or AbbVie.
As a result, the following metrics are not publicly established in audited filings:
| Financial metric |
Public disclosure status |
| Annual Rebyota revenue |
Not separately disclosed |
| Quarterly revenue |
Not separately disclosed |
| Net price |
Not consistently disclosed |
| Gross margin |
Not disclosed |
| Patient volume |
Not disclosed |
| Contribution profit |
Not disclosed |
| Sales and marketing expense |
Not disclosed |
| Product-level guidance |
Not disclosed |
The financial trajectory can therefore be assessed through commercial milestones rather than reported revenue.
Rebyota financial milestones
| Period |
Commercial or regulatory event |
Financial implication |
| 2018 |
Ferring acquired Rebiotix |
Ferring assumed development and commercialization investment |
| 2022 |
FDA approved Rebyota |
Converted development asset into commercial biologic |
| 2023 |
U.S. commercial launch |
Initiated sales, market access and provider education |
| 2023 onward |
Vowst entered the U.S. market |
Introduced direct competition and price-pressure risk |
| 2024 onward |
Expansion of payer and provider adoption |
Determines whether product revenue scales beyond early adopters |
The likely financial pattern is a slow initial ramp followed by a reimbursement-driven adoption curve. Rebyota is administered in a controlled clinical setting, so early sales depend on building treatment pathways rather than relying on ordinary retail pharmacy demand.
The product may produce strategic value for Ferring even before reaching blockbuster scale. It gives the company an early position in microbiome therapeutics and may support future products in inflammatory, infectious or gastrointestinal disease.
How does Rebyota compare with Vowst?
Vowst is the closest commercial substitute. The FDA approved Vowst, fecal microbiota spores, live-brpk, on April 26, 2023, for preventing recurrence of C. difficile infection in adults following antibacterial treatment for recurrent infection.[2]
| Attribute |
Rebyota |
Vowst |
| Active product |
Fecal microbiota, live-jslm |
Fecal microbiota spores, live-brpk |
| Delivery |
Rectal suspension |
Oral capsules |
| FDA approval |
November 30, 2022 |
April 26, 2023 |
| Developer |
Rebiotix/Ferring |
Seres Therapeutics |
| Current commercial owner |
Ferring |
Nestlé Health Science acquired Seres in 2024 |
| Treatment setting |
Clinic or healthcare facility |
Oral outpatient administration |
| Key advantage |
First approved microbiota product and clinical experience |
Convenience and no rectal administration |
| Key risk |
Administration burden |
Newer commercial and ownership history |
| Competitive overlap |
High |
High |
Vowst’s oral route is commercially important. It can reduce provider-administered treatment requirements and may simplify distribution through specialty pharmacy channels. Rebyota can counter with physician familiarity, its earlier approval and possible preference among providers who favor a directly administered product.
The competitive outcome is likely to depend less on regulatory differentiation than on payer coverage, contracting, treatment-center workflow and patient preference.
What is the Rebyota patent and exclusivity position?
Rebyota does not have a conventional small-molecule Orange Book exclusivity profile. The product is regulated as a biologic, so its key regulatory protections arise through the biologics framework rather than standard Hatch-Waxman listing.
Is Rebyota listed in the Orange Book?
No conventional Orange Book patent strategy should be expected for Rebyota. The FDA Orange Book primarily lists approved drug products and patent information under the drug-approval framework. Biologics approved under a BLA are generally tracked through the Purple Book rather than the Orange Book.[3]
The relevant competitive pathway is therefore a biosimilar or interchangeable biologic pathway, subject to the product’s regulatory classification and the FDA’s treatment of a complex, donor-derived microbiota product.
When does Rebyota lose biologic exclusivity?
The Biologics Price Competition and Innovation Act generally provides 12 years of reference-product exclusivity for eligible biologics, subject to statutory rules and FDA determinations. If the standard period applies from Rebyota’s 2022 approval, the relevant regulatory exclusivity window could extend into 2034. The exact competitive date depends on FDA reference-product treatment and any applicable exclusivity determinations.[4]
That exclusivity period does not eliminate all commercial competition. Vowst is a separately approved product, not a biosimilar to Rebyota. Competitors also may develop other microbiota-based products without relying on Rebyota’s approval.
What formulation and manufacturing barriers protect Rebyota?
The principal barriers are technical and operational:
- Donor screening and qualification
- Pathogen testing and release procedures
- Microbiota collection and processing
- Product consistency across donor material
- Stability and storage requirements
- Manufacturing controls for a complex biological mixture
- Clinical evidence demonstrating recurrence reduction
- Provider and payer acceptance
These barriers may be more commercially important than a single composition patent. Microbiota products are difficult to characterize using the same analytical framework applied to conventional drugs because the product contains a complex community of microorganisms.
Ferring and Rebiotix may hold patents covering manufacturing, processing, donor material, formulation, administration and methods of preventing recurrent infection. A definitive patent-by-patent freedom-to-operate assessment requires review of current U.S. and international patent records and claim status. Public FDA approval materials do not establish the complete enforceable patent estate.
Are there Paragraph IV challenges to Rebyota?
A conventional Paragraph IV challenge is not the primary expected pathway for Rebyota because Paragraph IV litigation is associated with Abbreviated New Drug Applications under the Hatch-Waxman Act. Rebyota is a biologic approved through a BLA.
Potential competition is more likely to arise through:
- A biosimilar application, if FDA determines the product is eligible for that pathway
- A separately developed microbiota product
- An oral or capsule-based microbiota therapy
- A live biotherapeutic product with a different manufacturing platform
- Non-FDA-regulated fecal microbiota transplantation in permitted clinical settings
No publicly established Paragraph IV litigation against Rebyota is identified in the core FDA approval record. That does not eliminate future patent disputes involving manufacturing methods, formulations or methods of use.
What litigation and settlement risks affect Rebyota?
The principal legal risks are regulatory classification, patent scope, manufacturing reproducibility and competition from alternative microbiome products.
There is no established public settlement framework comparable to major small-molecule generic settlements. Because Rebyota is not principally exposed to ordinary ANDA competition, commercial litigation risk is more likely to involve:
- Patent infringement claims against a competing microbiota product
- Trade-secret or manufacturing-process disputes
- Contract disputes involving donor material or manufacturing
- Product-liability claims
- Challenges involving advertising, reimbursement or medical claims
- Disputes over biosimilar or follow-on biologic eligibility
The absence of a known major Rebyota patent settlement reduces near-term legal visibility but does not remove long-term freedom-to-operate risk.
How does Rebyota’s geographic coverage affect growth?
Rebyota’s strongest commercial opportunity is the United States because the FDA created the first clear approval pathway for a standardized microbiota product. Geographic expansion is more complex.
| Region |
Commercial position |
| United States |
FDA-approved and commercially marketed |
| European Union |
Requires separate regulatory authorization and country-level reimbursement |
| United Kingdom |
Requires separate regulatory review and National Health Service adoption |
| Japan |
Requires local regulatory and clinical strategy |
| Canada |
Requires Health Canada authorization and payer access |
| Other markets |
Dependent on local classification of fecal microbiota products |
Ferring’s global infrastructure supports expansion, but reimbursement and regulatory classification vary by country. Some jurisdictions treat microbiota products as biological medicines, while others have historically regulated fecal microbiota transplantation through medical, tissue or controlled clinical frameworks.
What generic entry risks exist for Rebyota?
Near-term generic substitution risk is low relative to conventional drugs. The more significant threat is product substitution.
High-risk competitive events
- Broader adoption of Vowst because of oral administration.
- Development of lower-cost microbiota products.
- Expansion of live biotherapeutic products with defined microbial strains.
- Payer policies that favor one microbiota product over another.
- Provider reluctance to establish rectal administration workflows.
- Improved antibiotic or antibody strategies that reduce the need for microbiota restoration.
Low-risk events
- Immediate conventional generic substitution
- Automatic pharmacy substitution
- Short-term erosion from an ANDA filer
- Direct biosimilar competition before regulatory and manufacturing standards mature
Rebyota’s economic protection therefore depends on clinical differentiation, manufacturing scale and payer contracts as much as on statutory exclusivity.
How strong is the Rebyota commercial position?
Rebyota has a strong first-mover position but a moderate commercial moat.
| Factor |
Assessment |
Rationale |
| FDA status |
Strong |
First FDA-approved product in its class |
| Clinical need |
Strong |
Recurrent C. difficile has substantial morbidity and cost |
| Route of administration |
Moderate to weak |
Rectal delivery creates operational friction |
| Competitive intensity |
Moderate to high |
Vowst is a direct approved competitor |
| Patent visibility |
Unclear |
Biologic and process protection is more complex than Orange Book protection |
| Manufacturing barrier |
Strong |
Donor screening and product consistency are difficult |
| Payer leverage |
Uncertain |
Coverage determines practical treatment volume |
| Revenue transparency |
Weak |
Ferring does not disclose standalone product sales |
| Long-term differentiation |
Moderate |
Depends on outcomes, convenience and real-world evidence |
Key Takeaways
- Rebyota is FDA-approved fecal microbiota, live-jslm, for preventing recurrent C. difficile infection in adults after antibacterial treatment.
- Ferring Pharmaceuticals owns the commercial opportunity through its Rebiotix business.
- The product launched in a new market with no mature historical revenue benchmark.
- Ferring has not publicly disclosed standalone Rebyota revenue, units, margins or product-level guidance.
- Vowst is the principal competitor and has an important convenience advantage because it is administered orally.
- Rebyota faces low conventional generic risk but meaningful substitution risk from oral microbiota products and live biotherapeutics.
- Orange Book and Paragraph IV mechanisms are less central because Rebyota is a biologic approved under a BLA.
- Manufacturing, donor screening, product consistency and payer access are major commercial barriers.
- The financial trajectory is likely determined by reimbursement and treatment-pathway adoption rather than by regulatory approval alone.
FAQs about Rebyota market potential and exclusivity
How much does Rebyota cost?
The publicly relevant commercial price depends on contracting, payer terms and administration fees. Ferring has not provided a publicly audited net-price figure that can be used as a universal market price.
Is Rebyota a live biotherapeutic product?
Rebyota is a fecal microbiota biological product containing live microorganisms derived from human stool. It differs from defined-strain live biotherapeutic products because its microbial composition is more complex.
Can Rebyota be substituted automatically at the pharmacy?
Automatic substitution is unlikely to operate like substitution for conventional small-molecule generics. Rebyota is administered rectally in a healthcare setting and is not an ordinary retail pharmacy product.
Does Vowst replace Rebyota?
Vowst is a direct competitor but does not automatically replace Rebyota. The choice depends on route preference, payer policy, clinical workflow and provider judgment.
Could a biosimilar of Rebyota enter before 2034?
A follow-on product could face substantial regulatory and manufacturing barriers. A separate microbiota product may enter without being a biosimilar, while the timing and applicability of a biosimilar pathway depend on FDA determinations.
References
- U.S. Food and Drug Administration. (2022, November 30). FDA approves first fecal microbiota product. https://www.fda.gov
- U.S. Food and Drug Administration. (2023, April 26). FDA approves first orally administered fecal microbiota product for prevention of recurrence of C. difficile infection. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Ferring Pharmaceuticals. (2023). Rebyota prescribing information. https://www.rebyota.com